A Randomized Trial of Mometasone Furoate 0.1% to Reduce High-Grade Acute Radiation Dermatitis in Breast Cancer Patients Receiving Postmastectomy Radiation.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

A 2-arm, double-blinded randomized trial was conducted to evaluate the efficacy of 0.1% mometasone furoate (MF) versus Eucerin Original (E) cream in preventing the development of moderate to severe acute radiation dermatitis (ARD) in breast cancer patients receiving postmastectomy radiation (PMRT).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Int J Radiat Oncol Biol Phys

Title: International journal of radiation oncology, biology, physics

Publisher: Elsevier BV

ISSN (Electronic): 1879-355X

ISSN (Print): 0360-3016

Publication date (Electronic): Jun 01 2018

Volume: 101

Issue: 2

Affiliations

[1 ] Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA. Electronic address: Alice.Ho@mgh.harvard.edu.

[2 ] Department of Oncology Access, University of Colorado Health, Aurora, Colorado.

[3 ] Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.

[4 ] Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

[5 ] Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA.

[6 ] Department of Nursing, Memorial Sloan Kettering Cancer Center, New York, New York.

[7 ] Department of Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Article

Publisher Item ID: S0360-3016(18)30253-0

DOI: 10.1016/j.ijrobp.2018.02.006

PubMed ID: 29726361

SO-VID: 249f43d2-6706-45a1-85c7-8fc78a050bad

History

Data availability:

Comments

Comment on this article

Cited by 26

See all cited by

- Version 1